METHODS FOR TREATING HEPATOCELLULAR CARCINOMA
The present invention provides methods and compositions for treating hepatocellular carcinoma (HCC) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating HCC comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent, such as an agent that inhibits microtubule disassembly.
1 . A method of treating hepatocellular carcinoma (HCC) in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin.
2 . The method of claim 1 , further comprising administering to the individual an effective amount of at least one other agent, wherein said other agent inhibits microtubule disassembly.
3 . The method of claim 2 , wherein the nanoparticle composition and the other agent are administered simultaneously or sequentially.
4 . The method of claim 2 , wherein the nanoparticle composition and the other agent are administered concurrently.
5 . The method of claim 2 , wherein the other agent inhibits a molecule that promotes microtubule disassembly directly or indirectly.
6 . The method of claim 2 , wherein the other agent inhibits a molecule selected from the group consisting of ABP1, ARHGAP4, HSPA8, LCP1, PACSIN2, RUNX1T1, STMN1, and Tubulin, and TUBB4.
7 . The method of claim 6 , wherein the other agent is an inhibitor of STMN1.
8 . The method of claim 7 , wherein the other agent is an siRNA against STMN1.
9 . The method of claim 7 , wherein the other agent is a gamboge or a derivative thereof.
10 . The method of claim 2 , wherein the other agent activates a molecule that promotes microtubule assembly directly or indirectly.
11 . The method of claim 2 , wherein the other agent activates a molecule selected from the group consisting of ABI1, BCL2L11, CDC42, CHRM3, CNN3, CSMD1, DDOST, DOCK7, EHMT2, ENAH, ERMAP, ERLF1, HDAC5, LDLRAP1, MCF2, OLA1, RASA1, SHC2, STMN2, and TRIP10.
12 . The method of claim 1 , wherein the HCC is liver cell carcinoma, fibrolamellar variant of HCC, or mixed hepatocellular cholangiocarcinoma.
13 . The method of claim 1 , wherein the HCC is early stage HCC, non-metastatic HCC, primary HCC, advanced HCC, locally advanced HCC, metastatic HCC, HCC in remission, recurrent HCC, HCC in an adjuvant setting, or HCC in a neoadjuvant setting.
14 . The method of claim 1 , wherein the composition comprising nanoparticles comprising a taxane and albumin is administered parenterally.
15 . The method of claim 14 , wherein the composition comprising nanoparticles comprising a taxane and albumin is administered intravenously, intraarterially, intrahepatically, or intraportally.
16 . The method of claim 1 , wherein the taxane is paclitaxel.
17 . The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.
18 . The method of claim 17 , wherein the nanoparticles in the composition have an average diameter of less than about 200 nm.
19 . The method of claim 1 , wherein the taxane in the nanoparticles are coated with albumin.
20 . The method of claim 1 , wherein the individual is human.
21 . A kit comprising a) a composition comprising nanoparticles comprising a taxane and an albumin, and b) instruction for administering the nanoparticle composition for treatment of HCC.